Abstract
Sanford et al. reported results from an interviewassisted survey of chronic myeloid leukemia (CML) patients, which indicated that neither treatment compliance nor the occurrence of side effects significantly affected patient willingness to stop tyrosine kinase inhibitor treatment1.[...]
Highlights
We do not believe the sample is representative of the cml patient group who might be eligible to stop treatment
With respect to the measurement tool, we contend that there are flaws in many of the measures used, which may undermine the validity of the results
The first two measures of patient preferences for relapse rates are confounded with willingness to stop treatment
Summary
We do not believe the sample is representative of the cml patient group who might be eligible to stop treatment. The first two measures of patient preferences for relapse rates are confounded with willingness to stop treatment. These items reveal assumptions that all patients are willing to stop treatment, and that risk acceptability is the most important indicator of this willingness, overriding all other concerns. Assuming patients were presented with these scales, the results are difficult to interpret.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
